Earnings Releases·Nov 9, 2026, 8:02 AM ET

Delcath Systems — Third Quarter 2026 Earnings Summary

Total revenue surged 70.4% year-over-year to $35.1 million, driven by a 72% increase in HEPZATO KIT volume, while net income rose to $7.0 million and non-GAAP adjusted EBITDA more than doubled to $11.5 million.
The company raised its 2026 full-year revenue guidance to $115–$117 million, projecting positive adjusted EBITDA for the year and gross margins between 87% and 89%.
Clinical momentum advanced with the dosing of the first patient in the global Phase 2 DELUMA trial for breast cancer and plans to submit an IND application for cholangiocarcinoma in early 2027.
The balance sheet remains robust with $104.3 million in cash and investments and zero debt, though R&D and SG&A expenses increased to $11.0 million and $13.1 million, respectively.